De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SI-BONE Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

SI-BONE heeft een totaal eigen vermogen van $164.7M en een totale schuld van $36.1M, wat de schuld-eigenvermogensverhouding op 21.9% brengt. De totale activa en totale passiva bedragen respectievelijk $223.8M en $59.1M.

Belangrijke informatie

21.9%

Verhouding schuld/eigen vermogen

US$36.15m

Schuld

Rente dekkingsratio	n/a
Contant	US$151.53m
Aandelen	US$164.73m
Totaal verplichtingen	US$59.11m
Totaal activa	US$223.84m

Recente financiële gezondheidsupdates

Recent updates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Sep 25

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Apr 01

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Feb 28

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Nov 12

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Aug 09

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Apr 20

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Jan 01

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Sep 24

SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?

Apr 19

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Jan 05

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Oct 05

Does SI-BONE (NASDAQ:SIBN) Have A Healthy Balance Sheet?

Jul 05

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $202.3M ) SIBN } overtreffen de korte termijn passiva ( $22.1M ).

Langlopende schulden: De kortetermijnactiva SIBN ( $202.3M ) overtreffen de langetermijnschulden ( $37.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: SIBN heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van SIBN is de afgelopen 5 jaar gedaald van 50.3% naar 21.9%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: SIBN heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: SIBN heeft voldoende kasruimte voor meer dan 3 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 9.6 % per jaar.

SI-BONE Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Recent updates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Revises Financial Guidance for 2024

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

New minor risk - Profitability

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2026

CEO & Director recently sold US$809k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 7.3% to US$28.38

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Executive Chairman exercised options and sold US$337k worth of stock

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

Executive Chairman notifies of intention to sell stock

CEO & Director recently sold US$189k worth of stock

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$616k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold US$224k worth of stock

President of Commercial Operations notifies of intention to sell stock

Executive Chairman exercised options and sold US$5.1m worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Key Executive notifies of intention to sell stock

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 16% to US$24.50

President of Commercial Operations notifies of intention to sell stock

CEO & Director recently sold US$226k worth of stock

Executive Chairman notifies of intention to sell stock

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Price target decreased to US$22.38

Executive Chairman recently sold US$105k worth of stock

CEO & Director notifies of intention to sell stock

Third quarter 2022 earnings: EPS exceeds analyst expectations

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Executive Chairman recently sold US$138k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite